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Objective: Peripheral bone mineral density (BMD) may be decreased in early rheumatoid arthritis (RA) but it is
unknown whether BMD loss emerges before arthritis is clinically apparent. We aimed to study whether BMD loss
occurs in patients with clinically suspect arthralgia (CSA), and whether it is associated with progression to clinical
arthritis and magnetic resonance imaging (MRI)-detected subclinical inflammation.
Method: Patients with CSA had arthralgia for <1 year and were at risk of progressing to RA according to their
rheumatologists. At baseline, a 1.5 T MRI was performed of unilateral metacarpophalangeal, wrist, and metatarsopha-
langeal joints, and scored on synovitis, bone marrow oedema, and tenosynovitis;. summing these features yielded the
total MRI inflammation score. Digital X-ray radiogrammetry (DXR) was used to estimate BMD on two sequential
conventional hand radiographs (mean interval between radiographs 4.4 months). The change in BMD was studied;
BMD loss was defined as a decrease of ≥2.5 mg/cm2/month. Patients were followed for arthritis development for a
median of 18.4 months.
Results: In CSA patients (n = 108), change in BMD was negatively associated with age (β = −0.03, p = 0.007). BMD
loss in CSA patients was associated with arthritis development [adjusted for age hazard ratio (HR) = 6.1, 95%
confidence interval (CI) 1.7 to 21.4] and was most frequently estimated in the months before clinical arthritis
development. The total MRI inflammation scores were associated with the change in BMD (adjusted for age
β = −0.05, p = 0.047). The total MRI inflammation score and BMD loss were both independently associated with
arthritis development (HR = 1.1, 95% CI 1.1 to 1.2, and HR = 4.6, 95% CI 1.2 to 17.2, respectively).
Conclusion: In CSA patients, severe BMD loss is associated with MRI-detectable subclinical inflammation and with
progression to clinical arthritis.
Processes that underlie the development of rheumatoid
arthritis (RA) are already active in the symptomatic
phase before arthritis is clinically evident. In this
phase, pro-inflammatory cytokines may be elevated,
and auto-antibodies and subclinical inflammation may
be present (1, 2). Whether bone metabolism is chan-
ged in the phase preceding clinical arthritis is less
clear, but it has previously been reported that several
biomarkers of bone and cartilage metabolism (carti-
lage oligomeric matrix protein, N-terminal telopeptide
of type I procollagen, and osteoprotegerin) were
altered (3, 4).
Bone mineral density (BMD) loss of the hands (meta-
carpal bones II–IV) can be estimated with digital X-ray
radiogrammetry (DXR) (5). Previous studies revealed
that the association of radiographic progression with
BMD estimated by DXR is stronger than that of BMD
measured by dual-energy X-ray absorptiometry (DEXA)
of periarticular metacarpal bones (6). BMD loss has
been associated not only with radiographic progression
in early RA (7), but also with RA development in
patients presenting with undifferentiated arthritis (8).
Clinically suspect arthralgia (CSA) patients have
no clinical arthritis and are at risk of progressing
towards RA according to the rheumatologist (2, 10).
This study aimed to address whether BMD loss is
present in CSA and, if so, whether BMD loss is
preferentially present in CSA patients who progress
to clinically detectable arthritis. As MRI-detected
subclinical inflammation in CSA has been strongly
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associated with progression to RA (2, 11), the study
also explored whether subclinical inflammation is
associated with a decrease in BMD.
Method
Patients
Patients were included in the Leiden Clinically Suspect
Arthralgia (CSA) cohort between April 2012 and August
2014. As described previously (10), this inception cohort
was set up to study the symptomatic phase of RA before
clinical arthritis emerges. Inclusion criteria were the
presence of arthralgia of small joints for <1 year and
an increased risk of progressing to RA according to the
clinical expertise of the rheumatologists (2, 10). Patients
were not included when clinically detectable arthritis
was present or when another explanation for arthralgia
was more likely. Patients had a visit at baseline and after
4, 12, and 24 months. If indicated, patients were seen in
between visits to evaluate arthritis development. At all
scheduled visits, a physical examination was performed,
radiographs were made, and blood samples were
obtained. MRI was performed at the baseline visit. Fol-
low-up ended at 24 months, or earlier when clinical
arthritis had developed. This outcome was verified in
the medical files until 24 December 2014. The medical
ethics committee of the Leiden University Medical Cen-
ter approved this study. All patients provided written
informed consent.
Digital X-ray radiogrammetry
Radiographs of both hands, taken in the posteroanterior
position (at baseline and the first consecutive visit), were
used to estimate BMD with DXR. In brief, DXR is an
automated analysis of the cortical bone at the centres of
metacarpal bones II–IV; this technique has been
described in detail previously (5). The mean BMD
change of both hands was calculated as the difference
per month between the first two radiographs (mg/cm2/
month), as described previously (8, 9). BMD change
was analysed as a continuous measure and was dichot-
omized, with a decrease in BMD of ≥2.5 mg/cm2/month
defined as BMD loss (8, 9).
MRI and scoring
At baseline, contrast-enhanced magnetic resonance
images were made of unilateral metacarpophalangeal
(MCP) 2–5 joints, wrist joints, and metatarsophalangeal
(MTP) 1–5 joints, as described earlier (10). A detailed
scan protocol is provided in the Supplementary methods.
The more painful side was scanned or, in cases of
equally severe symptoms on both sides, the dominant
side. An ONI MSK extreme 1.5T extremity MRI scan-
ner (GE, Wisconsin, USA) was used.
Inflammation [synovitis, bone marrow oedema
(BMO) and tenosynovitis] was scored according to the
Rheumatoid Arthritis Magnetic Resonance Imaging
Scoring system (RAMRIS) (13, 14). Synovitis and
BMO were scored in MCP, wrist, and MTP joints, and
tenosynovitis was scored in the MCP and wrist joints.
The total MRI inflammation score was calculated by
summing the BMO, synovitis, and tenosynovitis scores
of all scored joints. The mean MRI scores, performed by
two trained independent readers (HWvS and LM)
blinded for any clinical data, were used. For the total
MRI inflammation score, the within-reader intraclass
correlation coefficient (ICC) was 0.98 and 0.99, and
the between-reader ICC was 0.96.
Analyses
The unpaired t-test, Mann–Whitney U test, and chi-
squared test were used as appropriate. Univariable and
multivariable linear regression models were used to study
associations between inflammation and BMD change. Uni-
variable and multivariable Cox proportional hazard regres-
sion analyses were used to determine associations with
arthritis development. To prevent overfitting of the data,
the multivariable Cox regression contained only age as an
adjustment factor. Data were analysed using IBM SPSS
statistics version 20 (IBM Corp., Armonk, NY, USA).
Results
Patients
In total, 162 patients were consecutively included in the
CSA cohort. Of these, 116 patients had conventional
radiographs taken at baseline and follow-up (mean time
interval 4.4 months ± SD 1.3 months). Radiographs of
eight patients could not be studied by DXR owing to
different acquisition settings of the radiographs when the
images were taken. Therefore, DXR results were
obtained from 108 CSA patients in total. The 108 CSA
patients who were studied and the 54 CSA patients who
were excluded did not differ in their baseline character-
istics (Table 1). The median follow-up of the studied
patients was 18.6 months (interquartile range 14.4–
25.0 months).
BMD change and age
A higher age was associated with a larger decrease in
BMD (β = −0.03, p = 0.007) (Figure 1A). No statisti-
cally significant difference in BMD change was
observed between genders (mean females = −0.18,
males = 0.003, p = 0.60), rheumatoid factor (RF) status
(mean RF-positive = −0.89, RF-negative = −0.079,
p = 0.06), and anti-citrullinated protein antibody
(ACPA) status (median ACPA-positive = −0.23,
ACPA-negative = −0.09, p = 0.58).
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MRI-detected inflammation and BMD decrease
The total MRI inflammation score at baseline was asso-
ciated with BMD decrease during the first months of
follow-up (β = −0.07, p = 0.018) (Table 2); β = −0.07
indicates that for each point increase in total MRI
inflammation, the BMD decreased by 0.07 mg/cm2/
month. The association remained after adjustment for
age (β = −0.05, p = 0.047). Studying the MRI-detected
inflammatory features separately revealed that synovitis
and tenosynovitis scores were associated with BMD loss
(β = −0.18, p = 0.008 and β = −0.19, p = 0.006, respec-
tively), in contrast to the BMO score (β = −0.03,
p = 0.63).
The association between BMD loss in one hand and
MRI inflammation of the metacarpal bones of the
same metacarpals was studied in a subanalysis (Sup-
plementary Figure S1). This analysis revealed similar
results to those presented above (see Supplementary
Table S1).
BMD loss and progression to clinical arthritis
Twenty (19%) CSA patients developed clinically appar-
ent arthritis after a median interval of 1.7 months (range
0.4–15.0 months), and 15 of these fulfilled the 1987
criteria for RA. BMD loss was present in five (4.6%)
of the CSA patients, of whom three developed arthritis.
BMD loss was more often present in CSA patients who
progressed to clinically apparent arthritis than in CSA
patients who did not progress [hazard ratio (HR) = 4.94,
95% confidence interval (CI) 1.44 to 16.97] (Figure 1B).
After adjustment for age, the HR of BMD loss was 6.01
(95% CI 1.72 to 21.38) (Table 3). Furthermore, the
association of BMD loss and arthritis development was
independent of MRI inflammation (HR = 4.62, 95% CI
1.24 to 17.20) (Table 3).
Six patients converted to clinical arthritis 1 month after
inclusion in the CSA cohort and these patients had the




(n = 54) p
Age (years), mean ± SD 44.5 ± 12.9 40.4 ± 12.3 0.057
Female, n (%) 81 (75) 39 (72) 0.70
TJC, median (IQR)* 5.0 (3.0–10.0) 5.5 (3.0–8.0) 0.92
CRP, median (IQR) 0.0 (0.0–4.6) 0.0 (0.0–4.3) 0.98
RF positive, n (%) 24 (22) 13 (24) 0.79
ACPA positive, n (%) 14 (13) 12 (22) 0.13
Total MRI inflammation, median (IQR) 2.0 (1.0–5.5) 2.0 (0.5–4.9) 0.43
Total synovitis score, median (IQR) 1.0 (0.0–2.5) 1.0 (0.0–2.8) 0.67
Total BMO score, median (IQR) 0.5 (0.0–1.5) 1.0 (0.0–1.5) 0.81
Total tenosynovitis score, median (IQR) 0.0 (0.0–2.0) 0.0 (0.0–1.0) 0.33
TJC, tender joint count; IQR, interquartile range; CRP, C-reactive protein; RF, rheumatoid factor; ACPA, anti-citrullinated protein









































Figure 1. (A) Association between age and bone mineral density
(BMD) decrease, and (B) the development of clinical arthritis in
clinically suspect arthralgia (CSA) patients with and without increased
BMD loss.
(A) The correlation coefficient of age with BMD loss was −0.03
(p = 0.007). (B) BMD loss was defined as a decrease in BMD of
≥2.5 mg/cm2/month. The upward increase of the line indicates that
patients had progressed to clinical arthritis. The vertical marks on the
line indicate that a patient was censored, which indicates wich indicates
the end of follow-up of that patient.
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second radiograph taken 2–3 months after arthritis devel-
opment. A sensitivity analysis excluding these patients
revealed similar results (Supplementary Table S2).
Discussion
Studying patients with arthralgia at risk for RA can
increase the understanding of the processes that are
active in the earliest symptomatic phase of RA. In this
light, this study evaluated BMD loss, estimated at the
metacarpals using DXR. We observed that BMD loss
was present in CSA, that BMD loss was more often
present in the CSA patients who progressed to arthritis
than in patients who did not progress, and that MRI-
detected subclinical inflammation was associated with a
decrease in BMD.
BMD loss was mostly estimated using radiographs
taken in the months preceding the development of
clinical arthritis. Therefore, our study mainly evaluated
the last preclinical phase and does not allow conclusions
on the presence of bone loss in earlier, asymptomatic,
preclinical phases.
We showed that MRI-detected subclinical inflamma-
tion was associated with a decrease in BMD and that
BMD loss was associated with arthritis development.
A multivariable analysis showed that MRI-detected
inflammation and BMD loss were both independently
associated with progression to clinical arthritis, suggest-
ing that both are markers of processes that are active in a
very early phase of RA.
This study is the first to assess BMD loss in CSA
patients. Only some of the CSA patients progressed to
arthritis and most patients did not progress. This explains
why the average decrease in BMD observed in this study is
lower than previously reported in RA (8, 9,15).
The cut-off value for BMD loss that we used was
suggested by the manufacturer and based on data
from studies in RA; age was not included in this
cut-off. A very recent study assessed variation in
BMD in the general population and established age-
and gender-adjusted reference values (14). Applying
these cut-off values revealed that 46% (n = 50) of the
CSA patients had BMD loss, but that BMD loss was
equally present in CSA patients who did not progress
to arthritis and in those who did progress (HR 0.99
(95% CI 0.41 to 2.38, p = 0.98). Hence, this did not
increase the discriminative ability in the present
population.
The most important limitation of this study is the
sample size. A small proportion of patients progressed
to clinical arthritis during the follow-up period and BMD
loss was also infrequent. Further studies are therefore
needed to confirm the present findings.
Conclusion
Severe BMD loss is increased in CSA patients progres-
sing to clinical arthritis and is associated with MRI-
detectable subclinical inflammation.
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